-
2023-509963-25-00
4
2025-01-17
Fluoropyrimidine (FP)-naive patients with gastrointestinal (GI) cancer
-
2024-512442-41-00
9
2024-12-03
Colorectal Carcinoma, Biliary Tract Carcinoma, Hepatocellular Carcinom
-
2024-512895-36-00
5
2024-11-25
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
-
2023-509912-27-00
5
2024-11-07
Metabolic Dysfunction-Associated Steatotic Liver Disease(MASH) / Nonal
-
2023-510395-31-00
5
2024-10-30
Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Compensat
-
2024-514606-31-00
4
2024-10-29
Patients with Biopsy-proven or radiologically-suggested BCLC A HCC eli
-
2024-515300-39-00
4
2024-10-18
METASTATIC GRADE 3 POORLY DIFFERENTIATED NEUROENDOCRINE CARCINOMA OF G
-
2023-509334-19-00
5
2024-10-17
gastro-enteropancreatic neuroendocrine tumors (GEP-NETs)
-
2024-511070-68-01
5
2024-09-24
Ampullary adenocarcinoma
-
2023-504415-33-00
9
2024-06-25
Patients aged 15 years and 3 months and older with severe head trauma
-
2023-508100-38-00
5
2024-06-24
Advanced Biliary Cancer (ABC)
-
2023-504600-28-00
10
2024-05-09
Metastatic Hepatocellular Carcinoma (HCC)
-
2023-505660-11-00
5
2024-04-24
Cholangiocarcinoma (LTT, 26.0)
-
2023-507073-18-00
4
2024-04-24
Cirrhosis
-
2024-516150-22-00
4
2024-04-11
HIV
-
2024-515768-30-01
4
2024-03-28
Hepatocellular carcinoma
-
2023-505141-48-00
5
2024-03-07
Fibrosis
-
2023-504208-27-00
5
2024-02-12
Community-acquired pneumonia
-
2024-516443-57-00
4
2023-10-11
Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh B, ALBI gr
-
2022-501943-34-00
5
2023-06-27
Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
-
2024-514929-33-00
5
2023-03-27
PANCREATIC FISTULA
-
2022-500643-20-00
4
2022-09-27
Patients with locally advanced, metastatic or unresectable hepatocellu
-
2024-513327-16-00
5
2022-09-20
Intensive care
-
2023-506081-31-00
5
2022-03-29
Traumatic Injury